Cyclooxygenase-2 Activation Mediates the Proangiogenic Effect of Nitric Oxide in Colorectal Cancer

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2694-2704

  Cianchi, Fabio ^a,b   Cortesini, Camillo ^a   Fantappiè, Ornella ^a   Messerini, Luca ^a   Sardi, Iacopo ^a   Lasagna, Nadia ^a   Perna, Federico ^a   Fabbroni, Valentina ^a   Di Felice, Annamaria ^a   Perigli, Giuliano ^a   Mazzanti, Roberto ^a   Masini, Emanuela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliero Universitaria Careggi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ARACHIDONIC ACID; CD31 ANTIGEN; CELECOXIB; CYCLIC GMP; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITRATE; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; AMIDINES; ANTIGENS, CD31; ARACHIDONIC ACID; BENZYLAMINES; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; MICROCIRCULATION; MIDDLE AGED; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TREATMENT OUTCOME; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11144355454     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0192     Document Type: Article

References (53)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Polverini PJ, Strieter RM. Role of proangiogenic cytokines and inhibitors of neovascularization in tumor angiogenesis. In: Voest EE, D'Amore PA, editors. Tumor angiogenesis and microcirculation. New York: Marcel Dekker, 2001. p. 265-84.
3. Williams CW, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270:G393-400.
4. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenase: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
5. Koki AT, Leahy KM, Harmon JM, Masferrer JL. Cyclooxygenase-2 and cancer. In: Harris RE, editor. COX-2 blockade in cancer prevention and therapy. Totowa: Humana Press, 2003. p. 185-203.
6. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
7. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley B, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 1994;81:1219-23.
8. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
9. Gullino PM. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol 1995;34:439-41.
10. 2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001;286:923-8.
11. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Phramacol 2000;130:641-9.
12. Nathan C, Xie QW. Nitric oxide synthase: roles, tolls, and controls. Cell 1994;78:915-8.
13. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4.
14. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
15. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic. Biol Med 2000;28:1387-404.
16. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
17. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-23.
18. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003;9:73-8.
19. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392-6.
20. Fukumura D, Jain RK. Role of nitric oxide in angiogenesis and microcirculation in tumor. Cancer Met Rev 1998;17:77-89.
21. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-96.
22. Cianchi F, Cortesini C, Fantappie O, et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 2003;162:793-801.
23. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-34.
24. Ziche M, Morbidelli L, Masini E, Granger HJ, Geppetti P, Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993;15:437-42.
25. Sugimoto Y, Narumiya S, Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000;39:289-314.
26. 1 in osteoblast. J Clin Invest 1994;93:2490-6.
27. Popovici RM, Irwin JC, Giaccia AJ, Giudice LC. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab 1999;84:2245-8.
28. 2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001;31:203-12.
29. Amano H, Ando K, Minamida S, et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001;87:181-8.
30. Salvemini D, Misko TP, Masferrer JL, Seibert K, Curie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993;90:7240-4.
31. Weinberg JB. Nitric oxide synthase 2 and cyclooxygenase 2 interaction in inflammation. Immunol Res 2000;22:319-41.
32. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 1996;93:15069-74.
33. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001;7:1325-32.
34. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
35. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A. Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas Biochem Biophys Res Commun 2002;299:517-24.
36. Bing RJ, Miyataka M, Rich KA, et al. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res 2001;7:3385-92.
37. Liu Q, Chan STF, Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 2003;24:637-42.
38. American Joint Committee on Cancer: AJCC cancer staging manual. Philadelphia: Lippincott, 1997.
39. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
40. Jenkins DC, Charles SA, Baylis SA, Lelchuk R, Radomski MW, Moncada S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994;70:847-9.
41. Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumor cell invasion. Br J Cancer 2002;86:1310-5.
42. Salvemini D, Mollace V, Pistelli A, Anggard E, Vane J. Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1992;89:982-6.
43. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
44. Pradelles P, Grassi J, MacLouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985;57:1170-5.
45. Bani D, Masini E, Bello MG, Bigazzi M, Bani Sacchi TB. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res 1995;55:5272-5.
46. Steiner AL, Parker CW, Kipnis DM. Radioimmunoassay for cyclic nucleotides. J Biol Chem 1972;247:1106-13.
47. Harper JF, Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′O acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1975;1:207-18.
48. Fantappiè O, Masini E, Sardi I, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002;35:843-51.
49. Pertschuk LP, Feldman JG, Kim DS, et al. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer 1993;71:162-71.
50. 2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003;306:887-97.
51. Mittermayer F, Pleiner J, Schaller G, et al. Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans. Eur J Clin Invest 2003;33:758-61.
52. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
53. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.